TIL: Instil Bio Inc Market Cap to Earnings

Corporate emblem and logo of Instil Bio, Inc (TIL)

Instil Bio, Inc. (TIL) is developing innovative cancer treatment methods, yet the lack of stable earnings and reliance on cash reserves leave its finances vulnerable. The stock's price history demonstrates the -1.40 metric. Strict FDA regulations and the high cost of laboratories create a high barrier to entry, while the automation of bioreactors in clean zones is designed to minimize personnel errors during drug production.

Instil Bio (TIL) - P/E Multiple from 07/04/2022 to 11/10/2026

Analytical breakdowns for Instil Bio, Inc.

- current quotes and average value forecast:
Price Rate Chart instilbio.com|TIL - Consensus Target
- market capitalization information:
Market Value Instil Bio, Inc.|TIL - Real Price to Acquire Entire Company
- book value of equity indicators:
Accounting Value of a Share Instil Bio|TIL - Book Capitalization|Market Cap to Net Assets Ratio instilbio.com|TIL - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Instil Bio, Inc.|TIL - Long-Term Debt to Equity|Short-Term Debt to Equity Instil Bio Inc|TIL - Company Debts|Debt to Book Capitalization Ratio Instil Bio, Inc.|TIL - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Instil Bio|Critical Liquidity instilbio.com
- earnings and valuation multiples indicators:
TIL - Net Profit|Expected Net Profit Instil Bio, Inc.|TIL - Price to Earnings Ratio|Price to Future Earnings Ratio Instil Bio Inc.|TIL - PEG Multiple|Company Value to EBITDA Instil Bio, Inc.|TIL - Operating profit before deduction of amortization|Earnings per share for the trailing year Instil Bio|TIL - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months instilbio.com|TIL - Earnings growth in current year|Expected earnings per share trend next year Instil Bio, Inc.
Comprehensive company analysis:instilbio.com
Original product of Instil Bio Inc

Fundamental analysis methodology requires separating speculative movements from the actual value of a business. This indicator measures the market value of a single unit of net profit, determining the extent of the asset's overvaluation. By analyzing the price-to-earnings ratio, an investor assesses the rate of return on capital. For Instil Bio, Inc. (TIL), this metric reflects market expectations regarding the commercialization of their innovative personalized therapy for solid tumors.

Competing companies

LEGN - Market Cap to Net Income Ratio|Price to Earnings Ratio SANA (Sana Biotechnology, Inc.)|AUTL - Market Cap to Earnings|Allogene Therapeutics Inc - Price to Earnings Ratio|Company Value to Net Income RNAC|Cellectis Biotherapeutics - P/E Multiple|cariboubio.com (CRBU) - Price to Earnings Ratio|GNTA: P/E Multiple|Market Cap to Earnings Century Therapeutics, Inc. (IPSC)|Price to Earnings Ratio Jasper Therapeutics Inc|Price to Earnings Ratio SNTI|Price to Earnings Ratio Adaptimmune (ADAP)|Price to Earnings Ratio CERO (cero.bio)|Alaunos Therapeutics, Inc. - Price to Earnings Ratio|Company Value to Net Income ACHL|Cargo Therapeutics - P/E Multiple|Market Cap to Net Income Ratio Poseida Corp (PSTX)|TSVT: P/E Multiple|Market Cap to Earnings gracellbio.com (GRCL)